NATCO Pharma Completes Acquisition of Additional 13.25% Stake in South Africa’s Adcock Ingram

Synopsis: NATCO Pharma has completed the acquisition of an additional 13.25% stake in South African pharmaceutical company Adcock Ingram Holdings for approximately Rs. 1,060 crore, taking its total shareholding in the company from 35.75% to 49%.

Indian pharmaceutical companies have increasingly pursued inorganic expansion into emerging markets like Africa and Latin America as a route to diversify beyond the intensely competitive and pricing-pressured US generics market, seeking exposure to less penetrated healthcare markets with established local brands and distribution networks.

Shares of Natco Pharma Ltd, with a market capitalization of Rs. 17,337.84 crore, are trading at a price of Rs. 967.50, down 1.27% from its previous closing price of Rs. 979.95. The stock touched an intraday high of Rs. 983.50 and a low of Rs. 966.50. It is trading at a P/E ratio of 12.79.

What’s the News?

In a filing to the BSE and NSE dated July 14, 2026, NATCO Pharma announced the successful completion of its acquisition of an additional 13.25% equity stake in Adcock Ingram Holdings Proprietary Limited, a leading South African pharmaceutical and healthcare company.

The transaction was completed through NATCO Pharma South Africa Proprietary Limited, the company’s wholly owned South African subsidiary, involving the acquisition of shares for an aggregate consideration of approximately ZAR 1.81 billion, translating to roughly Rs. 1,060 crore at the prevailing transaction exchange rate.

This latest purchase builds on NATCO’s original 35.75% stake in Adcock Ingram, which the company first acquired through its participation in Adcock Ingram’s delisting process in 2025, following a firm intention offer announced in July 2025, shareholder approval in October 2025, and completion of that initial transaction in November 2025.

The company’s board had approved this additional 13.25% stake acquisition in July 2026, and the transaction has now closed following satisfaction of customary closing conditions and regulatory requirements, taking NATCO’s total holding in Adcock Ingram to 49%.

Financial & Business Analysis

At Rs. 1,060 crore, this acquisition represents a meaningful capital deployment for NATCO, whose FY26 consolidated net profit stood at Rs. 1,418 crore, meaning the transaction size equals roughly 75% of a full year’s profit, a significant single commitment even for a company that remains largely debt-free with a debt-to-equity ratio of just 0.08.

NATCO’s balance sheet shows the capacity to absorb this deal comfortably, with free cash flow of Rs. 1,379 crore in FY26 and a current ratio of 3.01, though the company’s cash and investments position will need to be watched over coming quarters to assess how much of its previously accumulated reserves this Africa strategy has consumed.

This acquisition lands at a time when NATCO’s own quarterly performance has softened considerably, with Q4 FY26 net profit falling 34.1% year-on-year to Rs. 269 crore and revenue declining 39.5% to Rs. 739 crore, a sharp deceleration from the strong FY25 base that makes continued strategic investment outside the core India-US generics business a notable capital allocation choice during a weaker operating quarter.

With NATCO’s stock trading at a price-to-earnings ratio of just 12.24, a steep discount to peers like Sun Pharma at 37.5x, Lupin at 19.76x and Cipla at 30.75x, the market appears to be pricing in continued earnings volatility, and how effectively NATCO integrates and monetizes its now-49% stake in Adcock Ingram could be an important factor in whether that valuation gap narrows over time.

Industry & Strategic Analysis

Adcock Ingram is a scaled, established South African pharmaceutical company with a 10% share of the private pharmaceutical market, leadership in the OTC segment, and the largest hospital and critical care products supplier position in South Africa, giving NATCO exposure to well-recognised household brands including Panado, Allergex and Myprodol rather than having to build market presence from scratch.

Raising its stake to 49% moves NATCO closer to, but still short of, a majority controlling position in Adcock Ingram, suggesting the company may be building toward eventual full or majority control while working within regulatory and structural constraints tied to South African corporate ownership rules or the original delisting transaction terms.

This deal reinforces what the company describes as its long-term Africa growth strategy, a diversification move that reduces NATCO’s dependence on the US generics and Para IV filing-driven business model that has historically driven its earnings volatility, evident in the sharp swings seen in its recent quarterly results.

Since Adcock Ingram also operates two manufacturing facilities in India alongside its three South African plants, NATCO could potentially unlock manufacturing and supply chain synergies between its existing Indian operations and this now-larger African subsidiary, though the company has not yet detailed specific integration or synergy plans in this disclosure.

Company Overview

NATCO Pharma Limited is a vertically integrated, research and development focused pharmaceutical company specializing in complex, niche therapeutic products across oncology, cardiology and neurology. Established in 1981 and headquartered in Hyderabad, the company operates nine manufacturing facilities certified by global regulators including the US FDA, and exports products to more than 50 countries, with a market capitalization of approximately $1.82 billion.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post NATCO Pharma Completes Acquisition of Additional 13.25% Stake in South Africa’s Adcock Ingram appeared first on Trade Brains.